Introduction

▼
Lamotrigine has a modest but signifi cant antidepressant eff ect [ 1 -4 ] and a prophylactic eff ect particularly for depressive relapse in bipolar disorders [ 5 -7 ] . The number needed to treat for prevention of any mood episode was calculated as 5-11 [ 8 ] . However, given the negative trial of manic state and the length of time for titration up to a therapeutic dose, lamotrigine is not indicated for the acute treatment of mania [ 9 ] . Therefore, lamotrigine has a diff erent therapeutic profi le compared to other mood stabilizers such as lithium, valproate and carbamazepine. Although therapeutic drug monitoring (TDM) of lamotrigine for epilepsy is recommended and the therapeutic levels are reported to be 3-14 μg/mL [ 10 ] , so far, no specifi c reference range has been reported for mood stabilizing eff ects of lamotrigine [ 10 ] . In the present study, we hypothesized that lamotrigine may have a therapeutic window for mood disorders. Introduction: Lamotrigine is widely used for mood disorders including bipolar disorder and major depression, but its therapeutic levels have yet to be determined. This study was conducted to investigate the hypothesis that lamotrigine may have a therapeutic window for mood disorders. Methods: 25 patients with mood disorders received lamotrigine for more than one year during which time plasma lamotrigine levels were measured at least once. Their mental state was retrospectively and regularly but blindly assessed using the Clinical Global Impression-Severity (CGI-S) scale. In order to investigate our hypothesis, we depicted the relationship between the last lamotrigine levels and the last CGI scores in 25 patients. If any, the potential therapeutic window was further investigated.
Results:
The relationship between the last lamotrigine levels and the last CGI scores in the 25 patients indicated the presence of a therapeutic window of lamotrigine from 5 to 11 μg/mL. The repeated measures of ANOVA reached a signifi cant tendency of the eff ects of lamotrigine levels within 5-11 μg/mL on better CGI-S scores, and the CGI-S scores at the last observation of the 15 patients whose lamotrigine levels were within 5-11 μg/mL were signifi cantly better than those of 10 patients whose lamotrigine levels were not within 5-11 μg/mL. Conclusion: These fi ndings suggest that lamotrigine may have a therapeutic window for patients with mood disorder from 5 to 11 μg/mL. levels on or close to the date when the last clinical records were described for the aforementioned retrospective CGI-S assessment. If the day of measuring lamotrigine and the date when the clinical records for the CGI-S assessment were described were diff erent, the diff erence was permitted if lamotrigine dose was unchanged between the day of measuring lamotrigine and the date when the clinical records for the CGI-S assessment were described. CGI-S scores were blind to lamotrigine TDM (by Y.K.) and CGI-S ratings (by T.T.) and were never infl uenced by lamotrigine TDM.
Subjects
As shown in • ▶ Table 1 , subjects were 25 patients (15 males and 10 females), aged between 26 and 69 years (mean = 44.9, SD = 12.9). 18 patients had bipolar II disorder (BPII), 2 had bipolar I disorder (BPI) and 5 had major depressive disorder (MD). Their CGI-S scores at 1 month before and just before starting lamotrigine ranged from 2 to 5 (mean = 3.5, SD = 0.8) and 3-5 (mean = 4.2, SD = 0.7), respectively. Just before starting lamotrigine, 18 patients had mood stabilizers other than lamotrigine, 15 patients had antidepressants, and 6 patients had antipsychotics. Lamotrigine was started in combination with these drugs. The starting dose of lamotrigine ranged from 12.5 to 50 mg/day (mean = 19.5, SD = 8.9), which was gradually increased to 50-400 mg/day (mean = 256.0, SD = 99.0) at the last observation.
Measurement of plasma lamotrigine levels
All the blood samples for measurement of plasma lamotrigine levels were taken approximately 12 h after the last dose of lamotrigine. All lamotrigine doses were unchanged for more than the 6 days which are required to obtain lamotrigine levels in a steady state. Valproate was combined with lamotrigine in 7 patients while carbamazepine was combined with lamotrigine in 2 patients, but their doses were unchanged for more than 2 months and their eff ects on lamotrigine levels also seemed to be in a steady state. The measurement of lamotrigine was performed using a HPLC system by a third party. The inter-and intra-assay coeffi cients of variation were 2.79 and 0.58 %, respectively.
Statistical analyses
In order to investigate our hypothesis that lamotrigine may have a therapeutic window for mood disorders, we depicted the relationship between the last lamotrigine level and the last CGI score in 25 patients. If any, using the potential therapeutic window, repeated measures of analysis of variance (ANOVA) were performed using the CGI-S scores at baseline (i. e., just before starting lamotrigine) and the last CGI-S scores as a dependent factor with the last lamotrigine levels (within the potential therapeutic window or not) as an independent factor. Secondly, the last CGI-S scores were compared between patients whose lamotrigine levels were within the potential therapeutic window and patients whose lamotrigine levels were not within the window by unpaired t-test.
Ethics
The study was approved by the ethics committee of Oita University Faculty of Medicine. All subjects gave written informed consent. 
Results
▼
• ▶ Table 1 shows patient demographics, lamotrigine levels and CGI-S scores in 25 patients.
• ▶ Fig. 1 shows the relationship between the last lamotrigine levels and the last CGI-S scores of 25 patients. Our visual inspection indicated the presence of a therapeutic window of lamotrigine from 5 to 11 μg/mL. Therefore, the following analyses were performed to use this range Fig. 2 ).
The last CGI-S scores of the 15 patients whose lamotrigine levels were within 5-11 μg/mL were signifi cantly lower than those of 10 patients whose lamotrigine levels were not within 5-11 μg/ mL (2.2 ± 0.6 vs. 2.9 ± 0.9, t = 2.45, p = 0.023). There were no signifi cant diff erences in gender rate (6 females and 9 males within 5-11 μg/mL vs. 4 females and 6 males without 5-11 μg/mL, p > 0.99), age (47.1 ± 12.8 years within 5-11 μg/mL vs. 41.6 ± 13.0 years without 5-11 μg/mL, t = − 1.04, p = 0.31), psychiatric diagnoses (MD:BPI:BPII; 4:1:10 within 5-11 μg/mL vs. 1:1:8 without 5-11 μg/mL, p = 0.59) or lamotrigine administration period until the last observation (22.4 ± 12.5 months within 5-11 μg/mL vs. 22.2 ± 8.8 months without 5-11 μg/mL, t = − 0.042, p = 0.97).
Discussion
▼
Our hypothesis that lamotrigine may have a therapeutic window for mood disorders was supported in the present study. The repeated measures of ANOVA failed to reach a signifi cant level, but they reached a signifi cant tendency. Moreover, the CGI-S scores at the last observation of the 15 patients whose lamotrigine levels were within 5-11 μg/mL were signifi cantly lower than those of 10 patients whose lamotrigine levels were not within 5-11 μg/mL. Other factors were not signifi cantly diff erent between the groups. These fi ndings suggest that 5-11 μg/mL may be therapeutic levels of lamotrigine eff ects for mood disorders.
Since the therapeutic levels of lamotrigine for epilepsy are reported to be 3-14 μg/mL [ 10 ] , this range was also applied to our data. As a result, there were no signifi cant fi ndings (data not shown). Although a large part of our data were within 3-14 μg/ mL, these fi ndings suggest that 5-11 rather than 3-14 μg/mL may be more appropriate for the therapeutic levels of lamotrigine for mood disorders. The main limitation is that this study was a retrospective naturalistic study. Further prospective studies are required which randomize patients to diff erent doses and evaluate plasma levels and subsequent response over a defi ned period. Moreover, it is unclear whether antidepressant eff ect and/or prophylactic eff ect of lamotrigine were assessed by CGI-S and a CGI-S measure is a limited assessment. Moreover, CGI assessment was not blind to the hypothesis that lamotrigine may be helping the patients. Also, the analysis did not control for confounding variables including comedications.
Conclusion
▼
The present fi ndings suggest that lamotrigine may have a therapeutic window for patients with mood disorder from 5 to 11 μg/mL.
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